Egualen

Drug Profile

Egualen

Alternative Names: Azuletil; Azuloxa; Egualene; KT1 32

Latest Information Update: 02 Apr 2001

Price : $50

At a glance

  • Originator Kotobuki Seiyaku
  • Developer Kotobuki Pharmaceutical
  • Class Antisecretories; Antiulcers; Azulenes; Sesquiterpenes; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Gastric ulcer

Most Recent Events

  • 02 Apr 2001 A preclinical study has been added to the Peptic Ulcer Disease pharmacodynamics section
  • 09 Apr 1997 A study in experimental gastritis has been added to the Peptic Ulcer Disease pharmacodynamics section
  • 17 Jan 1996 Preregistration for Gastric ulcer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top